<DOC>
	<DOCNO>NCT01919398</DOCNO>
	<brief_summary>The primary purpose study assess safety tolerability LY2940680 global recommend dose Japanese participant advance solid cancer .</brief_summary>
	<brief_title>A Study LY2940680 Japanese Participants With Advanced Cancers</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Have histological cytological evidence diagnosis solid tumor advance and/or metastatic . The participant must , judgment investigator , appropriate candidate experimental therapy available standard therapy fail provide clinical benefit disease Have presence measurable nonmeasurable disease define Response Evaluation Criteria Solid Tumors Guideline Version 1.1 Have adequate organ function Have discontinue previous therapy cancer , include chemotherapy , radiotherapy , cancerrelated hormonal therapy least 3 week ( 6 week mitomycinC nitrosoureas , 2 week palliative radiation therapy bone metastasis ) prior study enrollment , recover acute effect therapy Males must agree use medically approve barrier contraceptive precaution study 6 month follow last dose study drug Females child bear potential must agree use medically approve contraceptive precaution study 6 month follow last dose study drug ; negative serum pregnancy test â‰¤7 day first dose study drug A breastfeeding woman must breastfeed . If female stop breastfeed enters study , female must stop breastfeeding day first study drug administration least 6 month last administration Have estimate life expectancy , judgment investigator , permit participant complete 2 cycle treatment Are able swallow tablet Have receive treatment within 21 day study enrollment agent receive regulatory approval indication Have symptomatic central nervous system ( CNS ) malignancy metastasis . Participants treat brain metastasis eligible clinically stable regard neurologic function steroid cranial irradiation end least 14 day prior enrollment , surgical resection perform least 28 day prior enrollment Have know current hematologic malignancy acute chronic leukemia Have know active fungal , bacterial , and/or know viral infection include human immunodeficiency ( HIV ) viral ( A , B , C ) hepatitis , potentially affect conduct study Have second primary malignancy judgment investigator sponsor may affect interpretation result Have QTc interval &gt; 470 millisecond ( msec ) screen electrocardiogram ( ECG ) Have serious preexist medical condition serious concomitant systemic disorder , opinion investigator , would preclude participation study Have receive medication strong inhibitor cytochrome P4503A4 ( CYP3A4 ) within 7 day prior receive study drug</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>